http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Viking Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
-
Viking Therapeutics to Report Financial Results for Second Quarter 2021 on July 28, 2021
-
Viking Therapeutics (VKTX) Announces Initiation of Phase 1b Clinical Trial of VK0214 in Patients with X-ALD
-
Viking Therapeutics Announces Initiation of Phase 1b Clinical Trial of VK0214 in Patients with X-ALD
-
Viking Therapeutics (VKTX) Announces Results from Phase 1 Clinical Trial of Novel Oral Thyroid Receptor Beta Agonist VK0214
-
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Novel Oral Thyroid Receptor Beta Agonist VK0214
-
Viking Therapeutics to Participate in Upcoming Investor Conferences
-
Viking Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
-
Viking Therapeutics to Report Financial Results for First Quarter 2021 on April 28, 2021
-
Viking Therapeutics to Present at 20th Annual Needham Virtual Healthcare Conference
-
Viking Therapeutics to Participate at Upcoming Investor Conferences
-
Viking Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update
-
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2020 on February 17, 2021
-
Viking Therapeutics Announces Senior Management Team Appointments
-
Viking Therapeutics to Present at H.C. Wainwright BioConnect 2021 Conference
-
Viking Therapeutics to Present at Stifel Healthcare Conference 2020
-
Viking Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
-
Viking Therapeutics to Report Financial Results for Third Quarter 2020 on October 28, 2020
-
Viking Therapeutics (VKTX) Begins Phase 1 Clinical Trial of VK0214
-
Viking Therapeutics Announces Initiation of Phase 1 Clinical Trial of VK0214
-
Viking Therapeutics to Participate in Upcoming Investor Conferences
-
Viking Therapeutics (VKTX) Highlights New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol
-
Viking Therapeutics Presents New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The Digital International Liver Congress�
-
Viking Therapeutics (VKTX) to Present New Data from Phase 2 Study of VK2809 in Patients with NAFLD and Elevated LDL-Cholesterol at The Digital International Liver Congress 2020
-
Viking Therapeutics to Present New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The Digital International Liver Congress
-
Viking Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
-
Viking Therapeutics to Participate in Upcoming Investor Conferences
-
Viking Therapeutics to Report Financial Results for Second Quarter 2020 on July 29, 2020
-
Viking Therapeutics to Participate in Upcoming Investor Conferences
-
Viking Therapeutics Announces 2020 Annual Meeting of Stockholders to be Held as Virtual Meeting
-
Viking Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
-
Viking Therapeutics to Participate in Upcoming Investor Conferences
-
Viking Therapeutics to Report Financial Results for First Quarter 2020 on April 30, 2020
-
Viking Therapeutics to Participate in 19th Annual Needham Healthcare Conference
-
Viking Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update
-
Viking Therapeutics to Participate in Upcoming Investor Conferences
-
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2019 on February 26, 2020
-
Viking Therapeutics to Present at Biotech Showcase 2020
-
Viking Therapeutics (VKTX) Begins Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis
-
Viking Therapeutics Announces Initiation of Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
-
Viking Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
-
Viking Therapeutics to Report Financial Results for Third Quarter 2019 on November 5, 2019
-
Viking Therapeutics to Present at 2019 Cantor Global Healthcare Conference
-
Viking Therapeutics to Participate in Upcoming Investor Conferences
-
Viking Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
-
Viking Therapeutics to Report Financial Results for Second Quarter 2019 on August 1, 2019
-
Viking Therapeutics Appoints Kathy Rouan, Ph.D., to Board of Directors
-
Viking Therapeutics to Participate in Upcoming Investor Conferences
-
Viking Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
-
Viking Therapeutics to Participate in Upcoming Investor Conferences

